EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prescribing Metformin to Prevent Antipsychotic-Induced Weight Gain – a Clinical Audit and Clinician Stakeholder Event

Sarah Fynes-Clinton, Piyumi Dona, Zoe Scabbiolo, Jakov Zlodre, Monty Lyman

BJPsych Open · 2026-06 · 12 (S1) · S294-S294

DOI: 10.1192/bjo.2026.11718 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BJPsych Open, online erschienen am 30.06.2026. Verfasst von Sarah Fynes-Clinton und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Antipsychotic-induced weight gain (AIWG) is common, contributes substantially to cardiometabolic morbidity, and is a major cause of treatment discontinuation. Recent international consensus guidelines recommend metformin for the prevention of AIWG in high-risk patients. This project examined whether eligible inpatients were being identified, whether metformin was being discussed, and whether it was being initiated in line with these recommendations.

Methods

A retrospective audit (April-June 2025) was conducted on an acute psychiatric ward to identify patients meeting criteria for pharmacological prevention of AIWG. Following an education-based intervention for clinicians, a re-audit was completed (June-September 2025). Data were extracted from electronic health records. A clinician questionnaire was administered at a stakeholder event involving psychiatry and GP trainees (n=18) to explore barriers and facilitators to preventative metformin prescribing.

Results

At baseline, 60% (27/48) of patients met criteria for preventative metformin, yet only one patient had a documented discussion and one was initiated on treatment. Following the intervention, 64% (32/57) met criteria. Of those that met criteria, documented discussions increased to 34% (11/32), and initiation rose to 9% (3/32). Among clinicians surveyed, 94% (16/17) reported not routinely prescribing metformin preventatively. Key barriers included absence of local guidelines (78%), concerns about polypharmacy (56%), and perceived reluctance in primary care to continue prescribing (33%).

Conclusion

Despite clear eligibility and international guidance, preventative metformin prescribing for AIWG remained uncommon, with education alone producing only modest improvements. Barriers appear primarily structural and inter-professional rather than evidence based. Development of local guidelines and improved psychiatrist-GP communication may be necessary to translate international recommendations into routine clinical practice.

Zitieren

APA

Fynes-Clinton, S., Dona, P., Scabbiolo, Z., Zlodre, J., & Lyman, M. (2026). Prescribing Metformin to Prevent Antipsychotic-Induced Weight Gain – a Clinical Audit and Clinician Stakeholder Event. BJPsych Open, 12(S1), S294-S294. https://doi.org/10.1192/bjo.2026.11718

Vancouver

Fynes-Clinton S, Dona P, Scabbiolo Z, Zlodre J, Lyman M. Prescribing Metformin to Prevent Antipsychotic-Induced Weight Gain – a Clinical Audit and Clinician Stakeholder Event. BJPsych Open. 2026;12(S1):S294-S294. doi:10.1192/bjo.2026.11718

BibTeX
@article{FynesClinton2026,
  author = {Fynes-Clinton, Sarah and Dona, Piyumi and Scabbiolo, Zoe and Zlodre, Jakov and Lyman, Monty},
  title = {Prescribing Metformin to Prevent Antipsychotic-Induced Weight Gain – a Clinical Audit and Clinician Stakeholder Event},
  journal = {BJPsych Open},
  year = {2026},
  volume = {12},
  number = {S1},
  pages = {S294--S294},
  doi = {10.1192/bjo.2026.11718}
}
Kostenlos starten →